Compound Glutaral Solution Veterinary Grade API, model CG-VET-50, is supplied as a clear, colourless-to-pale-yellow aqueous liquid in which the active dialdehyde, glutaral, is present at a nominal 50.0% w/w with a pH maintained between 3.0 and 4.5 to limit oligomerization during storage. The molecule is a saturated five-carbon dialdehyde, CAS 111-30-8, with two terminal carbonyl functions; this structure distinguishes it from formaldehyde, which is a volatile monoaldehyde, and from ortho-phthalaldehyde, which carries the reactive carbonyl functions on an aromatic ring. The veterinary-grade API is positioned as a processing intermediate for tablets, injectable multi-dose preparations where authorized, capsules, powders, granules, premixes, and solutions rather than as a terminal ready-to-use disinfectant. Release of the material is controlled for free carbonyl titre, residual methanol, elemental impurities, and sub-visible filterability because these parameters directly affect downstream blending, capsule dissolution, and sterile filtration. Industrial-grade glutaral solutions often contain oligomeric aldehyde populations that are not distinguished from monomeric glutaral by a simple aldehyde titration; the veterinary-grade material therefore includes a filtration and oligomer-control step verified by membrane throughput testing on a 0.45 µm mixed cellulose ester filter under a constant differential pressure of 0.7 bar.

Which Compendial Specifications and Test Methods Define the Release Profile for Veterinary-Grade Glutaral Solution?

Assay of the veterinary-grade API is performed by hydroxylamine hydrochloride derivatization followed by potentiometric titration according to USP <541>; the result is calculated as free glutaral on the anhydrous basis. pH is measured with a calibrated glass electrode in accordance with USP <791>, and density is determined at 25.0 °C by the oscillating transducer technique of USP <841>. Refractive index, when used as a rapid identity check, is read at 20 °C and controlled at n_D20 1.375–1.385, although it is not considered a stability-indicating parameter because oligomer formation does not shift the refractive index proportionally to free aldehyde loss. Residual methanol is quantified by headspace gas chromatography with flame-ionization detection under USP <467>; the veterinary-grade limit is set at ≤0.5% w/w to reduce volatile organic carbon contribution to finished premixes and to limit feed refusal in poultry and swine. Elemental impurities are assessed according to USP <232> and <233> with limits aligned to ICH Q3D; this replaces the older unsulfated ash or heavy metals limit commonly applied to industrial product. Microbial enumeration is performed under USP <61> and specified-objectionable-organism testing under USP <62>. For injectable-grade lots, bacterial endotoxins are controlled by USP <85> or Ph. Eur. 2.6.14 at a limit established from the maximum intended dose of the finished injectable product; no universal endotoxin limit is assigned without a target product profile.

These specifications differ from industrial product acceptance criteria in that the veterinary API grade is tested against ICH Q3D elemental impurity classes rather than a simple unsulfated ash limit. The filterability test detects oligomeric glutaral populations that can form during prolonged storage above 25 °C; a lot that passes the chemical assay but blocks a 0.45 µm filter is rejected for injectable, solution, or high-shear granulation use. Because glutaral tends to form aldol condensation products when the pH rises above 4.5, the release pH is not merely a compendial identifier but a direct predictor of storage stability and membrane processability.

Free Carbonyl Equivalents in Medicated Feed Premixes and Their Effect on Blend Uniformity

In premix manufacture, the liquid API is sprayed onto a carrier such as precipitated silica, corncob meal, or lactose monohydrate at a loading not exceeding 250 mL/kg unless vacuum drying is used to remove added water. Blend uniformity is typically assessed at 10 sampling points with an acceptance criterion of ≤5.0% RSD for the glutaral titre, consistent with current powder blend guidance for finished dosage units. When the carrier is calcium carbonate, the acidic glutaral solution reacts slowly with the carbonate surface, generating carbon dioxide and causing sack swelling in closed containers; calcium carbonate carriers are therefore not recommended for premixes above 100 g/kg active loading unless the mixture is vented for at least 24 hours before final packaging. For granules, a fluidized-bed spray granulator with top-spray configuration and inlet air temperature of 40–55 °C is preferred over high-shear granulation when free aldehyde retention is critical; high-shear processing can generate local temperatures above 35 °C at the chopper tip, accelerating aldol addition and lowering the free carbonyl assay by 2–4% relative to the theoretical charge. Published data for this exact configuration is limited; the range is an internal process-qualification window rather than a compendial requirement.

Tablets are manufactured either by direct compression after adsorption of the glutaral solution onto microcrystalline cellulose or by wet granulation using the API as a binder. In wet granulation, the liquid addition rate must remain below 2.5% w/w of dry granulate per minute to avoid overwetting; above this rate, granule size distribution widens and wet-mill screen blockage occurs on a 1.0 mm screen. The resulting granules are dried in a fluid-bed dryer at an inlet air temperature of 45–60 °C to a residual moisture content not exceeding 3.0% w/w. For capsules, gelatin shell compatibility is a release-critical parameter because free glutaral reacts with lysine residues in gelatin, increasing shell crosslink density and slowing disintegration below the USP <701> acceptance criterion. Hydroxypropylmethylcellulose capsules are preferred when the fill contains more than 0.1% w/w free glutaral; gelatin capsules may still be used if the fill is dry granulated and residual moisture is maintained below 2.0% w/w.

Powders for oral solution or topical administration are prepared by adsorbing the API onto maltodextrin or lactose monohydrate; bulk density is adjusted to 0.45–0.65 g/cm³ to maintain acceptable flow through a rotary tablet press or powder filling line. If the powder is packaged in single-dose sachets, residual moisture is limited to ≤2.0% w/w to prevent caking and to slow the liberation of glutaral vapour into the headspace. For solutions, the API is diluted with purified water and pH-adjusted with citrate or phosphate buffer to the range specified by the veterinary monograph. Alkaline activation before use increases the biocidal activity of glutaral because the unprotonated dialdehyde reacts more readily with primary amino groups, but activated solutions have a limited use-life of 14–28 days at 25 °C due to progressive polymer deposition.

For injectable multi-dose preparations where glutaral is authorized as a preservative, the solution is sterile-filtered through a 0.22 µm polyvinylidene fluoride membrane under aseptic conditions. Terminal steam sterilization is not recommended unless the pH remains below 5.5, because alkaline conditions cause the dialdehyde to polymerize into insoluble resin during heating. Stainless steel contact surfaces should be passivated and inspected after each campaign because glutaral can deposit a thin polymeric film on unpassivated steel at pH above 6.0. The final injectable solution must be protected from light in Type I glass or high-density polyethylene containers and must meet the endotoxin and sterility requirements of USP <71> and USP <85> where applicable.

Operational boundaries for the veterinary API are defined by its reactivity with nucleophiles. It is incompatible with primary amines, ammonia, and sulfite salts, which consume free aldehyde groups through exothermic addition; storage in unvented containers with such agents is contraindicated. Alkaline adjustment must be performed with buffered alkalinity rather than strong alkali added rapidly, because local pH excursions above 9.0 initiate uncontrolled aldol condensation and produce a yellow-to-brown resin deposit. The product is not intended for direct intravenous injection without microbially controlled dilution, pH adjustment, and endotoxin verification. For capsules, gelatin shell compatibility must be confirmed by two-point dissolution profiling under USP <711>; for tablets containing glutaral as a binder, residual moisture after drying should not exceed 3.0% w/w because residual water mobilizes the dialdehyde and accelerates crosslinking of film coatings. Where published data for a specific veterinary species or dosage form configuration is limited, formulation development should include forced-degradation studies at 40 °C/75% RH over 6 months to verify that free aldehyde loss remains within the approved assay window.